The US/China Trade Agreement: what could it mean for the Pharma Industry?

Following a long period of negotiation, Phase I of the US-China Trade Agreement was published on 15 January 2020. An important element of the negotiations from the US side had focussed on the need for China to recognise and strengthen the protection of intellectual property (IP) rights held by US companies in China. Chapter 1 of the Agreement is of particular relevance to pharmaceutical companies as it contains a broad range of measures that, if implemented into law and properly enforced, could have a significant beneficial effect for IP rights owners in China.

Latest insights

More Insights
Curiosity line teal background

Hong Kong’s Clinics to Prepare for Licensing Regime

Aug 13 2025

Read More
featured image

Women in Tech: At the forefront of innovation - Key takeaways from Dana Ghosn, Typeless

3 minutes Aug 07 2025

Read More
featured image

German Constitutional Court upholds pharmaceutical cost control measures: implications for drug pricing and reimbursement

5 minutes Aug 05 2025

Read More